Drugs / HJB647
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07644364 | Jun 2026 → Jan 2027 expected | hypertensive disorder | Novartis Pharmaceuticals | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07465653 | Mar → Sep 2026 overdue | symptomatic heart failure | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HJB647 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07644364 ↗ |
| Route | Oral | “Taken by mouth as capsule” NCT07465653 ↗ |